Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Moleculin's Annamycin Shows Breakthrough Results Against Drug-Resistant Leukemia in Key Study
Annamycin, a non-cardiotoxic anthracycline, shows efficacy against Cytarabine and Venetoclax-resistant AML, with a 60% CRc rate in relapsed/refractory patients. It exhibits synergy with Ara-C, lacks cardiotoxicity, and may induce immune memory, suggesting potential as a treatment option for high-risk AML patients.
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202
Senti Biosciences reports positive Phase 1 data for SENTI-202 CAR-NK therapy in R/R AML, with 2/3 patients achieving MRD-negative CR at the lowest dose level, and a well-tolerated safety profile. Dose escalation continues, with additional data expected in 2025.
Senti Bio Announces Positive Initial Clinical Data in Phase
Senti Biosciences reports positive Phase 1 data for SENTI-202, a CAR-NK therapy for R/R AML, with 2/3 patients achieving MRD-negative CR at the lowest dose level. The therapy is generally well-tolerated, and dose escalation continues with additional data expected in 2025.
Efficacy and safety of the combination of decitabine and CHAG priming regimen in the
The study evaluates decitabine combined with CHAG regimen for R/R AML, achieving CR in 74.2% and ORR of 82.2% with fewer side effects. Median RFS was 4.3 months and median OS was 7.75 months. The regimen showed deeper remissions, especially in patients with WT1 gene positivity, AML1-ETO fusion gene positivity, and NPM1 mutation. The study suggests a new treatment option for R/R AML but acknowledges limitations due to its single-center, retrospective nature and short observation time.
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R
Moleculin Biotech amends Phase 3 MIRACLE trial protocol with FDA, accelerating unblinding of preliminary primary efficacy data and safety/tolerability at 45 subjects, aiming for potential accelerated approval of Annamycin in combination with cytarabine for relapsed or refractory AML.
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute
Moleculin Biotech amends Phase 3 MIRACLE trial protocol with FDA, accelerating unblinding of preliminary efficacy data for Annamycin in R/R AML treatment, with first subject expected in Q1 2025.
Moleculin Biotech Accelerates Phase 3 AML Trial Data Timeline to H2 2025
Moleculin Biotech amends Phase 3 MIRACLE trial protocol with FDA, accelerating unblinding of preliminary efficacy data at 45 subjects for Annamycin in R/R AML treatment, aiming for potential accelerated approval and strategic partnering.
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial
Moleculin Biotech receives IRB approval for Phase 3 MIRACLE trial of Annamycin + Cytarabine for R/R AML, aiming for first subject treated in Q1 2025.
Moleculin's Breakthrough: FDA Fast-Track Cancer Drug Advances to Pivotal Phase 3 Trial
Moleculin Biotech received IRB approval for its Phase 3 MIRACLE trial evaluating Annamycin + Cytarabine for relapsed/refractory AML, aiming for first subject enrollment in Q1 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath